MERCK
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.
Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.
Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.
About Chord Therapeutics
Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. Chord is advancing its lead drug candidate, CRD1 (cladribine), for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and generalized myasthenia gravis (gMG). Chord Therapeutics was founded in 2014 and launched in October 2020 with Series A funding by its sole investor, Omega Funds, a leading international venture capital firm focused on delivering impactful medicines to patients.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meilleurtaux Enters Into a Definitive Agreement to Acquire Peasy, Creating the #1 Financial Services Champion for Household Finances in Belgium23.12.2025 07:00:00 CET | Press release
Combination unites two highly complementary platforms and creates the leading omnichannel brokerage platform for household finances in Belgium Meilleurtaux, a leading omnichannel financial services brokerage platform in France, Belgium, and Luxembourg backed by Silver Lake, today announced that it has entered into a definitive agreement to acquire Peasy, a leading omnichannel broker for household finances in Flanders. Together, Meilleurtaux and Peasy will form a scaled and unified platform designed to serve Belgian households across the full spectrum of their financial needs, including mortgage credit, consumer credit and insurance. This acquisition creates a national Belgian champion that combines Peasy’s local market leadership in Flanders through key brands such as Hypotheek.winkel and Verzekeringen.be, together with Meilleurtaux’s established presence in Wallonia. It represents a further milestone in the international expansion of Meilleurtaux, which first entered the Belgian marke
Comera Financial Holdings, Part of Abu Dhabi’s Royal Group, and SC Ventures Announce Strategic Collaboration to Explore Innovation in SME and Beyond23.12.2025 06:05:00 CET | Press release
Collaboration aims to co-create data-driven financial solutions, expand access to SME financing, and accelerate corporate innovation across the UAE’s evolving economic landscape. Comera Financial Holdings, part of Abu Dhabi’s Royal Group, and SC Ventures signed an MoU announcing a strategic collaboration to jointly explore new opportunities designed to strengthen the SME segment. The initiative reflects a shared vision to advance technology-driven financial solutions that align with the UAE’s economic priorities and support sustainable development across key sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222001568/en/ Akhtar Saeed Hashmi, Managing Director & Group CEO of Comera Financial Holdings, and Alex Manson, CEO of Standard Chartered Ventures, sign an MoU announcing a strategic collaboration. (Photo: AETOSWire) Through this collaboration, Comera Financial Holdings and SCV have outlined several areas where t
Lattice to Showcase its Latest FPGA Technology Innovations at the International VLSID Conference23.12.2025 01:50:00 CET | Press release
‒ Pravin Desale, Head of R&D, to Deliver Keynote on Growing Need for Low Power FPGAs ‒‒ Multiple Technical Sessions Focused on Edge AI, Sensor Fusion, System Design, and More ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming International VLSID Conference taking place January 3 – 7, 2026 in Pune, India. As part of the event, Lattice Senior Vice President of Research and Development Pravin Desale will deliver a keynote presentation exploring the market dynamics and trends that are positioning low power FPGAs at the forefront of technological advancements. Lattice will also have track sessions and panel discussions on low power FPGAs and AI from edge to cloud, and technology demonstrations with industry partners focused on advanced automotive and robotics applications. Who: Lattice Semiconductor What / When (GMT+2): Lattice Demo Showcase (Major Stall #B1), Jan 5 – 7 Keynote Jan. 5, 10:30 – 11 a.m. at Main Audit
First Cessna SkyCourier Delivered into Mexico, Expanding Air Freight Capabilities for FlexCoah22.12.2025 18:13:00 CET | Press release
The first Cessna SkyCourier in Mexico was recently delivered to cargo transportation provider FlexCoah for use by the company’s aviation subsidiary, Altair. The aircraft — a freighter variant — will expand the company’s air freight capabilities throughout the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222890759/en/ First Cessna SkyCourier delivered into Mexico, expanding air freight capabilities for FlexCoah (Photo Credit: Textron Aviation) The Cessna SkyCourier is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The Cessna SkyCourier’s combination of reliability, payload capacity and mission flexibility makes it a powerful asset for operators looking to scale their operations while maintaining cost-efficiency,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “The delivery of the Cessna SkyCourier to FlexCoah reflects the aircraft’s growing role in tran
Proudly Produced in Donegal: ProAmpac Invests in the Future of Food Board Manufacturing22.12.2025 17:34:00 CET | Press release
ProAmpac, a global leader in flexible packaging and material science, is strengthening its operational footprint with the expansion of Food Board manufacturing capabilities at its Donegal, Ireland campus. The addition of a new, purpose-built Food Board production area within the existing site reinforces ProAmpac’s commitment to innovation, efficiency, and customer service across the food packaging sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222149380/en/ Carr & Sons Smoked Salmon - ProAmpac As an extension of the existing Donegal operations, which support the pet food, food-to-go, and CPG markets, the expanded production area increases capacity and precision. A state-of-the-art guillotine system delivers cleaner cuts and consistent board quality, ensuring every sheet meets ProAmpac’s performance standards. The expanded facility area introduces several key improvements for customers: Dedicated Customer Service T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom